Core Insights - Liquidia Corporation reported strong financial results for the year ended December 31, 2025, highlighting the successful launch and adoption of YUTREPIA® in clinical practice, which has become one of the top specialty drug launches in recent years [2][5][10] Financial Performance - The company achieved net income of $14.6 million in Q4 2025, marking its second consecutive quarter of profitability, with a positive non-GAAP adjusted EBITDA of $27.3 million [5][10] - Total product sales for the year reached $148.3 million, with $90.1 million generated in the fourth quarter alone [6][10] - Cash and cash equivalents increased to $190.7 million as of December 31, 2025, up from $176.5 million in 2024 [5][10] Revenue Breakdown - Service revenue for the year was $10.0 million, down from $14.0 million in 2024, primarily due to lower sales volumes [7] - Cost of product sales was recorded at $8.8 million for 2025, with no costs associated with product sales in 2024 [8][10] - Research and development expenses decreased by 18% to $39.3 million, while selling, general, and administrative expenses rose by 93% to $157.2 million due to increased personnel and commercial expenses [12][13] Market Adoption and Growth Strategy - YUTREPIA has seen over 3,600 unique prescriptions and has treated more than 2,900 patients since its launch in June 2025, with a strong prescription-to-start conversion rate above 85% [10][11] - The company plans to deepen prescriber adoption, expand its sales force, and advance its L606 program into pivotal trials, all funded from operations [3][10] Product Information - YUTREPIA is an inhaled dry-powder formulation of treprostinil, indicated for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [17] - L606 is an investigational extended-release formulation of treprostinil, currently in clinical evaluation for PAH and PH-ILD [18]

Core Insights - Liquidia Corporation announced preliminary, unaudited full-year 2025 net product sales of YUTREPIA™ (treprostinil) inhalation powder, with a total of approximately $148.3 million in sales for the year and $90.1 million in the fourth quarter [1][5][6] - The company experienced a 74% quarter-over-quarter growth in net product sales, indicating strong market demand and physician confidence in YUTREPIA [6] - Liquidia plans to report fully audited financial results for the year ended December 31, 2025, in February 2026 [1] Financial Highlights - Estimated net product sales for YUTREPIA were approximately $90.1 million in Q4 2025 and $148.3 million for the full year [5][6] - Generated over $30 million in positive cash flow during Q4 2025 [5][6] - Cash and cash equivalents stood at approximately $190.7 million as of December 31, 2025 [6] Commercial Launch and Adoption - YUTREPIA was successfully launched for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [2] - The company received more than 2,800 unique patient prescriptions since the launch in June 2025, with over 2,200 patients starting treatment [5][6] - An 85% conversion rate from prescription to patient start was maintained for prescriptions received through the end of November 2025 [6] Clinical Pipeline and Future Plans - Liquidia aims to advance clinical programs for YUTREPIA and L606, targeting additional indications such as idiopathic pulmonary fibrosis (IPF), progressive pulmonary fibrosis (PPF), and pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) [3][5] - The company is initiating multiple open-label studies to evaluate YUTREPIA's efficacy in various patient groups, including those with inadequate responses to existing treatments [5][6] - Liquidia is also enrolling patients in the global pivotal Phase III study for L606, an investigational extended-release formulation of treprostinil [7]